Very late presentation in ST elevation myocardial infarction: Predictors and long-term mortality

Patrick W. McNair a,1, Kenneth C. Bilchick a,1, Ellen C. Keeley b,⁎,1

1. Introduction

Current guidelines recommend first medical contact (FMC) to device time of ≤90 min in the treatment of ST elevation myocardial infarction (STEMI) [1]. These guidelines underscore the importance of total ischemic time (time of vessel occlusion and symptom onset to the re-establishment of antegrade blood flow) and pre-hospital initiatives aimed to decrease it. Despite continued improvements in STEMI system-based care, total ischemic time remains unacceptably long in patients who are slow to recognize symptoms and seek medical attention. Prior studies assessing predictors of presentation delay in STEMI primarily focus on delays of ≤6 h [2–4]. However, the 12-hour mark after symptom onset remains relevant because it is the accepted timepoint used in decision-making regarding candidacy for reperfusion therapy [1]. The aim of this study was to determine predictors of very late (≥12 h) presentation of STEMI and to assess long-term mortality in this patient population.

2. Methods

2.1. Study design

The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the University of Virginia investigational review board. Due to the retrospective nature of the study protocol, the requirement for written informed consent from each patient was waived. We retrospectively examined consecutive patients admitted with STEMI to the University of Virginia using the ACTION Registry™ from January 2011 to December 2016. STEMI was defined by electrocardiogram (ECG) criteria as new ST segment elevation at the J-point in at least two contiguous leads of ≥0.2 mm in men or ≥1.5 mm in women or ≥1 mm in other leads [1]. Reasons for exclusion included: unresponsive or cardiac arrest at FMC, a diagnosis other than STEMI, and undocumented symptom onset time or symptom description.
2.2. Data collection

Demographics, co-morbidities, presenting symptom (presence or absence of chest pain), time of symptom onset, time of FMC, vital signs at FMC, laboratory and echocardiographic data, coronary angiographic data, in-hospital outcomes, and long-term all-cause mortality were collected. In-hospital outcomes included acute heart failure, cardiogenic shock, cardiac arrest, stroke, and death. Time of symptom onset to FMC was calculated for each patient and categorized as <12 h or ≥12 h.

2.3. Statistical analysis

Continuous variables are displayed as medians with interquartile ranges and compared with Wilcoxon Rank Sum test. Categorical variables are displayed as absolute values with percentages of the total and compared using Chi-Square or Fisher’s Exact test. Based on the two-group Wilcoxon Rank Sum or Chi-Square tests, clinically relevant differences between the two groups were evaluated with univariable logistic regression models. A stepwise, multivariable logistic regression was performed using a p-value < 0.2 to enter the model and a p-value of <0.05 to remain in the model. Odds ratios and 95% confidence intervals (CI) were calculated. Long-term survival curves using Kaplan-Meier methodology were constructed and compared using the log-rank test. Hazard ratios with 95% CI were calculated using Cox proportional hazards regression. Mortality at 1 year was compared using Chi-Square. Statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC).

3. Results

3.1. Patient characteristics

A total of 559 patients with STEMI between 2011 and 2016 were available in the ACTION Registry™ in our institution. A total of 145 were excluded (34 were unresponsive at FMC, 35 had a diagnosis other than STEMI, and 76 did not have their symptom onset or description documented). The analysis was based on the remaining 414 patients, of whom 365 (88%) had symptom onset to FMC time of <12 h, and 49 (12%) with symptom onset to FMC time of ≥12 h.

Nearly half of the very late presenters were women compared to those presenting <12 h. Those who presented very late were less likely to be referred for coronary angiography or to undergo PCI (Table 3). During the index hospitalization, they were also more likely to develop acute heart failure, have longer lengths of stay, were less likely to be discharged to home, and more likely to be discharged to a rehabilitation center. In multivariable analysis, diabetes, female sex, and absence of chest pain were strongly associated with late presentation (c-statistic = 0.70) (Table 4).

Median follow-up for the entire cohort was 2.8 years (IQR 1.1–4.6). Survival was significantly lower in very late presenters at 1-year follow-up (73% vs. 93%, log-rank p = 0.0001). A Kaplan-Meier survival curve showed increased long-term mortality in very late presenters (log-rank p = 0.007) (Fig. 1). Cox proportional hazard analysis calculated a hazard ratio of 2.3 (95% CI, 1.2–4.3, p = 0.009) for very late presenters compared to those presenting <12 h.

4. Discussion

We found that 12% of STEMI patients presented very late (<12 h) after symptom onset. Patients who presented very late were more likely to be women and diabetics, and were less likely to present with chest pain. We also found that patients who presented very late were less likely to call 911 and be transported by ambulance, suggesting they did not perceive their symptoms to be an emergency. Our results concur with prior reports focused on predictors of delayed presentation in STEMI [2–6], and now extend to patients who present very late.

Longer ischemic time has been associated with larger infarct size and increased mortality [7,8]. In a recent study, STEMI patients with pre-hospital delays of ≥12 h had worse left ventricular systolic function and higher rates of acute heart failure [5]. Similarly, we found

Table 1
Baseline patient characteristics.

| Variable                   | <12 h | ≥12 h | p-Value |
|----------------------------|-------|-------|---------|
| N = 365                    |       |       |         |
| Female sex                 | 101 (28%) | 23 (47%) | 0.006 |
| Age (years)                | 58 (50,68) | 61 (54,71) | 0.095 |
| Race                       |        |       | 0.380  |
| White                      | 306 (84%) | 37 (76%) |       |
| African American           | 42 (12%) | 7 (14%) |        |
| Hispanic                   | 8 (2%)  | 2 (4%)  |        |
| Asian                      | 9 (2%)  | 3 (6%)  |        |
| Body mass index (kg/m²)    | 29 (26,34) | 29 (25,33) | 0.535 |
| Family history of coronary artery disease | 203 (56%) | 26 (53%) | 0.738 |
| Tobacco use                | 256 (70%) | 34 (69%) | 0.914 |
| Hypertension               | 231 (63%) | 31 (63%) | 0.998 |
| Hyperlipidemia             | 169 (46%) | 26 (53%) | 0.373 |
| Diabetes mellitus          | 91 (23%) | 27 (55%) | <0.0001 |
| Chronic obstructive pulmonary disease | 33 (9%)  | 5 (10%)  | 0.791 |
| Prior coronary artery disease | 102 (28%) | 12 (24%) | 0.611 |
| Prior myocardial infarction | 82 (22%) | 7 (14%) | 0.191 |
| Prior percutaneous coronary intervention | 79 (22%) | 7 (14%) | 0.233 |
| Prior coronary artery bypass surgery | 9 (2%)  | 5 (10%) | 0.005 |
| Prior congestive heart failure | 22 (6%)  | 12 (24%) | 0.104 |
| End stage renal disease on dialysis | 6 (2%) | 0 (0%) | 1.000 |
| Prior stroke               | 22 (6%) | 5 (10%) | 0.348 |
| Peripheral arterial disease | 34 (9%)  | 3 (6%)  | 0.600 |
| Medications                |        |       |         |
| Aspirin                    | 123 (34%) | 15 (31%) | 0.716 |
| P2Y12 inhibitor            | 28 (8%) | 2 (4%) | 0.558 |
| Anticoagulation            | 16 (4%) | 3 (6%) | 0.475 |
| Beta-blocker               | 97 (27%) | 14 (29%) | 0.712 |
| Angiotensin converting enzyme inhibitor | 93 (25%) | 15 (31%) | 0.399 |
| Statin                     | 118 (32%) | 20 (41%) | 0.202 |

Data presented as number (%), median (IQR).

Table 2
Clinical data at first medical contact and test results.

| Variable                      | <12 h | ≥12 h | p-Value |
|-------------------------------|-------|-------|---------|
| N = 365                       |       |       |         |
| Heart rate (beats per minute) | 77 (65,90) | 89 (74,106) | 0.001 |
| Systolic blood pressure (mmHg) | 143 (124,167) | 133 (110,157) | 0.018 |
| Acute congestive heart failure | 49 (13%) | 10 (20%) | 0.189 |
| Cardiogenic shock             | 24 (7%) | 4 (8%) | 0.760 |
| Cardiac arrest                | 21 (6%) | 3 (6%) | 1.000 |
| Transported by EMS (air and ground) | 245 (67%) | 22 (45%) | 0.005 |
| First medical contact to device (minutes) | 93 (74,113) | 104 (75,121) | 0.264 |
| Chest pain                    | 312 (85%) | 35 (71%) | 0.012 |
| No chest pain                 | 53 (15%) | 14 (29%) |        |
| Chest pain within past 30 days | 120 (33%) | 11 (22%) | 0.141 |
| Initial troponin (ng/mL)      | 0.1 (0.08,11) | 11.9 (2.5,24.9) | <0.0001 |
| Peak troponin (ng/mL)         | 43 (17,91) | 37 (13,113) | 0.600 |
| Initial creatinine (mg/dL)    | 1.0 (0.8,11) | 1.0 (0.8,13) | 0.586 |
| Initial hemoglobin (g/dL)     | 14 (13,15) | 13 (12,51) | 0.033 |
| Left ventricular ejection fraction (%) | 48 (38,58) | 43 (33,53) | 0.003 |

Data presented as number (%), median (IQR).
that very late presenters had more hemodynamic compromise with higher heart rates and lower blood pressures on presentation. During the index hospitalization, very late presenters were found to have higher initial troponin levels, worse left ventricular systolic function, and higher rates of acute heart failure compared to patients who presented earlier, indicating a sicker patient population.

Previous evidence has associated increased pre-hospital delay with increased in-hospital mortality [9]. While we did not find a difference in in-hospital mortality between the groups, long-term mortality was significantly higher in very late presenters. This was largely driven by increased death within the first 6 months. We contend that very late presenters remain at increased risk for death after hospital discharge and may benefit from increased post-discharge surveillance. Our results are different from a recent study of long-term mortality in STEMI patients which did not find increased mortality in those presenting late, however, in this study “late” was defined as >60 min [6].

While prior studies have shown improved outcomes with revascularization in STEMI patients presenting between 12 and 48 h after symptom onset [10–12], current guidelines, partly based on the findings from the Occluded Artery Trial [13], recommend deferring reperfusion in patients presenting >12 h who do not show evidence of ongoing ischemia [1]. Nevertheless, reperfusion with primary PCI >12 h from symptom onset may attenuate the increased long-term mortality associated with very late presentation [11].

Despite significant reductions in door-to-balloon times through the mid-2000s [14,15], more recently this trend has plateaued [16], underscoring potential improvement possibilities within this metric. Despite impressive advances in STEMI care, a sizable proportion of patients (12% in our study) continue to present very late and are subjected to longer total ischemic times. While prior efforts to reduce pre-hospital delay have been suboptimal [17], novel educational initiatives regarding STEMI symptoms (including lack of chest pain) and the importance of seeking medical attention early should continue with a special focus on vulnerable populations, including women and diabetics.

4.1. Study limitations

Our study has several limitations. First, it was a retrospective study. Second, the population was predominantly white and our results may not be applicable to other patient populations. Third, symptom onset time was based on self-reported data which can be subject to recall bias. Fourth, we do not have information regarding the incidence of atrial fibrillation or mechanical complications of STEMI in our patient cohort.

5. Conclusions

Female sex, diabetes, and absence of chest pain are strong predictors of presentation delay in STEMI, and long-term mortality is significantly increased in those presenting very late.

Authors contributions

PWM and ECK designed this study. PWM collected data and entered it into a database. PWM, ECK and KCB analyzed the data. All authors wrote and critically revised the manuscript and all have approved the final submitted version.

Conflicts of interest

None.

Grant support

This work was supported by the American Heart Association, Dallas, Texas [13RG14560018 to E.C.K.].

References

[1] P.T. O’Gara, F.G. Kushner, D.D. Ascheim, et al., 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J. Am. Coll. Cardiol. 61 (2013) e78–140.
[2] H.H. Ting, E.H. Bradley, Y. Wang, et al., Factors associated with longer time from symptom onset to hospital presentation for patients with ST-elevation, Arch. Intern. Med. 168 (2008) 959–968.

[3] R.J. Goldberg, P.G. Steg, I. Sadiq, et al., Extent of, and factors associated with delay to hospital presentation in patients with acute coronary disease (The GRACE Registry), Am. J. Cardiol. 89 (2002) 791–796.

[4] C. Nielsen, K.G. Laut, L.O. Jensen, J. Ravkilde, C.J. Terkelsen, S.D. Kristensen, Patient delay in patients with ST-elevation myocardial infarction: time patterns and predictors for a prolonged delay, Eur. Heart J. Acute Cardiovasc. Care (2016) 1–9.

[5] E. Cerrato, D. Forno, S. Ferro, A. Chinaglia, Characteristics, in-hospital management and outcomes of late acute ST-elevation myocardial infarction presenters, J. Cardiovasc. Med. 18 (2017) 567–571.

[6] B. Jager, S. Farhan, M. Rohla, et al., Clinical predictors of patient related delay in the VIENNA ST-elevation myocardial infarction network and impact on long-term mortality, Eur. Heart J. Acute Cardiovasc. Care 6 (3) (2017) 254–261.

[7] A. Guerchicoff, S.J. Brener, A. Maehara, et al., Impact of delay to reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE AMI Trial (INFUSE-Anterior Myocardial Infarction), JACC Cardiovasc. Interv. 7 (2014) 733–740.

[8] A.E. Denktas, H.V. Anderson, J. McCarthy, R.W. Smalling, Total ischemic time: the correct focus of attention for optimal ST-segment elevation myocardial infarction care, JACC Cardiovasc. Interv. 4 (2011) 599–604.

[9] H.H. Ting, E.H. Bradley, Y. Wang, et al., Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction, Am. J. Med. 121 (2008) 316–323.

[10] A. Schomig, J. Mehilli, D. Antoniucci, et al., Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset, JAMA 293 (2005) 2865–2872.

[11] A. Schomig, G. Ndrepepa, A. Kastrati, Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction, Eur. Heart J. 27 (2006) 1900–1907.

[12] M. Gierlotka, M. Gasior, K. Wilczek, et al., Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms, Am. J. Cardiol. 107 (2011) 501–508.

[13] J.S. Hochman, G.A. Lamas, C.E. Buller, et al., Coronary intervention for persistent occlusion after myocardial infarction, N. Engl. J. Med. 355 (2006) 2395–2407.

[14] D.S. Menees, E.D. Peterson, Y. Wanj, et al., Door-to-balloon time and mortality among patients undergoing primary PCI, N. Engl. J. Med. 369 (2013) 901–909.

[15] A. Flynn, M. Moscucci, D. Share, et al., Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, Arch. Intern. Med. 170 (2010) 1842–1849.

[16] M.B. Yudi, G. Hamilton, O. Farouque, et al., Trends and impact of door-to-balloon time on clinical outcomes in patients aged ≥75, 75–84, and ≥85 years with ST-elevation myocardial infarction, Am. J. Cardiol. 120 (2017) 1245–1253.

[17] K. Dracup, S. McKinley, B. Riegel, et al., A randomized clinical trial to reduce patient prehospital delay to treatment in acute coronary syndrome, Circ. Cardiovasc. Qual. Outcomes 2 (2009) 524–532.